Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia

Contributed by: Business Wire

Logo

Images

Business Wire embedded0

Tags

Biotechnology

Pharmaceutical

Health

Clinical Trials

Agios Pharmaceuticals, Inc.

More Like This

Avanzanite Bioscience’s Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia

Adam Plich, Founder & CEO

Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders

Business Wire associated0

Avanzanite Bioscience Expands Partnership With Advicenne in Additional European Countries

Avanzanite Bioscience Reports European Commission's Authorisation of Orphan Medicinal Product AKANTIOR®

Adam Plich, Founder & CEO, Avanzanite Bioscience B.V. (Photo: Business Wire)

Avanzanite Bioscience Reports AKANTIOR® Received Positive CHMP Opinion and Announces Corporate Expansion Into 26 European Countries

Adam Plich, Founder and CEO of Avanzanite.

Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners

Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Vertex Announces Key Advancements Across Kidney Portfolio